Jefferies analyst Biren Amin lowered his price target for Regeneron Pharmaceuticals (REGN) to $343 from $376 after doctors in his firm's survey viewed Novartis' (NVS) brolucizumab favorably. Retina specialists are particularly eager to prescribe brolucizumab, Amin tells investors in a research note. "Conservatively" incorporating the doctor estimates for brolucizumab uptake cuts revenue for Regeneron's Eylea in wet age-related macular degeneration by 13% over next two years, says the analyst. His revised Eylea estimates are now 4%-7% below consensus for fiscal 2020 through 2023. Amin thinks the Street underestimates the impact of the brolucizumab entry, which he thinks could "replicate events seen when Eylea launched and encroached on Lucentis share." The analyst keeps a Hold rating on Regeneron.

Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.